Home
/
aTYR PHARMA INC
/
Financials
/
Quarterly
aTYR PHARMA INC — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that aTYR PHARMA INC filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$190.0K
Nov 6, 2025
Q2
2025
Jun 30, 2025
$0
Aug 7, 2025
Q1
2025
Mar 31, 2025
$0
May 7, 2025
Q3
2025
Sep 30, 2024
$0
Nov 6, 2025
Q2
2025
Jun 30, 2024
$0
Aug 7, 2025
Q1
2025
Mar 31, 2024
$235.0K
May 7, 2025
Q3
2024
Sep 30, 2023
$353.0K
Nov 7, 2024
Q2
2024
Jun 30, 2023
$0
Aug 13, 2024
Q1
2024
Mar 31, 2023
$0
May 2, 2024
Q3
2023
Sep 30, 2022
$0
Nov 9, 2023
Q3
2021
Sep 30, 2020
$148.0K
Nov 12, 2021
Q2
2021
Jun 30, 2020
$189.0K
Aug 11, 2021
Q1
2021
Mar 31, 2020
$8.07M
May 14, 2021
Q3
2020
Sep 30, 2019
$184.0K
Nov 13, 2020
Q2
2020
Jun 30, 2019
$94.0K
Aug 13, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($25.74M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($19.53M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($14.88M)
May 7, 2025
Q3
2025
Sep 30, 2024
($17.26M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($16.31M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($15.49M)
May 7, 2025
Q3
2024
Sep 30, 2023
($11.34M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($12.34M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($11.95M)
May 2, 2024
Q3
2023
Sep 30, 2022
($13.24M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($12.42M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($12.15M)
May 9, 2023
Q3
2022
Sep 30, 2021
($7.67M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($10.39M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($7.15M)
May 10, 2022
Q3
2021
Sep 30, 2020
($6.60M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($6.45M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
$1.75M
May 14, 2021
Q3
2020
Sep 30, 2019
($5.65M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
($5.85M)
Aug 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($26.75M)
Nov 6, 2025
Q2
2025
Jun 30, 2025
($20.31M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($15.77M)
May 7, 2025
Q3
2025
Sep 30, 2024
($18.14M)
Nov 6, 2025
Q2
2025
Jun 30, 2024
($17.32M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($16.64M)
May 7, 2025
Q3
2024
Sep 30, 2023
($12.62M)
Nov 7, 2024
Q2
2024
Jun 30, 2023
($13.56M)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($12.79M)
May 2, 2024
Q3
2023
Sep 30, 2022
($13.49M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($12.58M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($12.38M)
May 9, 2023
Q3
2022
Sep 30, 2021
($7.73M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($10.45M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($7.20M)
May 10, 2022
Q3
2021
Sep 30, 2020
($6.51M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($6.32M)
Aug 11, 2021
Q1
2021
Mar 31, 2020
$1.86M
May 14, 2021
Q3
2020
Sep 30, 2019
($5.50M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
($5.64M)
Aug 13, 2020